Navigation Links
Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
Date:7/22/2014

ces Group Analyst Emma McFadden, Ph.D.:

  • "Although it is still uncertain when, or even if, generic versions of Teva's Copaxone 20 mg will be approved by the FDA, neurologists indicated that they plan to switch approximately one-fifth of audit patients to generic glatiramer acetate once available. While it is not surprising that Copaxone 20 mg appears to be most at risk for generic switching, it is interesting to note that Tecfidera- and Tysabri-treated patients appear to be least likely to be switched, alluding to neurologists' perception that these products have characteristics that justify the additional cost or reimbursement effort."
  • "Analysis of candidates for the emerging monoclonal antibodies Genzyme/Sanofi's Lemtrada and Genentech/Roche's ocrelizumab suggests that these DMTs would likely be prescribed to patients with more severe/aggressive MS and potentially compete with Tysabri, the DMT typically initiated when efficacy reasons are the main drivers of brand choice. Given Tysabri's general position in the MS treatment algorithm as a third-line or later option, these emerging agents will be reserved primarily for patients who have failed earlier lines of therapy."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesg
'/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
2. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
3. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
4. Sinovac Reports Unaudited First Quarter 2012 Financial Results
5. SCOLR Pharma Announces Unaudited Net Sales of Nutritional Products
6. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
7. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2012 Results
8. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
10. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
11. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
(Date:7/1/2015)... 2015 Research ... addition of the "2015 New Frontiers ... Business Challenges, Emerging Technologies, Competitive Landscape" ... New Frontiers in European Clinical Chemistry and ... Landscape is a new five-country strategic analysis ...
(Date:7/1/2015)... , June 24, 2015 ... announced the addition of the "2015 Strategies ... their offering. This new 175-page report ... segments, including diabetes (strips and meters), pregnancy, ovulation, ... size, growth, regulatory requirements, technologies, and competitive profiles. ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 22015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 22015 Strategies in the Home/Self Testing Market 2
... p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., May ... ), a biopharmaceutical company focused on oncology, today reported ... 2009, and provided a corporate update. "The completion of ... picoplatin for the second-line treatment of small cell lung ...
... Burden of RSV Disease Presented at Pediatric Academic ... announced results from a recent study it sponsored, ... in Oakland, CA, assessing risk factors for respiratory ... infants born at 33 weeks gestational age [GA] ...
Cached Medicine Technology:Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 9MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants 2MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants 3
(Date:7/2/2015)... ... July 02, 2015 , ... It’s no secret that what we consume can have an effect on the body. ... easily feel dehydrated or perhaps even undernourished if not eating enough of the right foods, as ... an easy time of year to overdo it on the food front as well, with sweet ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... operated by the California Department of State Hospitals. Prior to using Winscribe’s dictation ... legacy hardwired telephone dictation system to manage their organization’s dictation and transcription processes. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... their products, services, channels and business models. To help manage the increasing demand ... addition of Mark Benkendorf as SVP of Strategic Engagements. , Benkendorf is a ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... complete, St. Joseph’s Health, located in Syracuse, N.Y., is now a member of ... have gained an admirable and important partner committed to delivering high-value care, said ...
(Date:7/1/2015)... New York, New York (PRWEB) , ... July ... ... drug injury lawsuit filed against the manufacturers of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has ... the U.S. District Court, Southern District of West Virginia on June 26th, the ...
Breaking Medicine News(10 mins):Health News:Iryna Lobur Shares Healthy Treats to Eat for Summer 2Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 2Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 3Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 4Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3
... ... 18 million Americans suffer from heavy snoring, but don’t realize it,s likely a tell-tale sign ... ... Americans suffer from heavy snoring, but don’t realize it may actually be a tell-tale sign ...
... 16 The 15th Annual National Ergonomics Conference ... - 20, will focus on the importance of workplace ergonomics ... topics of return on investment, the aging workforce, and safety ... offices and call centers, industrial, lab, healthcare, and uncontrolled environments ...
... It was found less effective than extended-release niacin, or ... new study raises more questions about ezetimibe (Zetia), a ... statins to lower LDL, or "bad," cholesterol. , The ... June after it was discovered that LDL-cholesterol-lowering Zetia was ...
... modern medicine finds a way to treat a medical condition, ... also have to find ways to get that treatment into ... research from North Carolina State University shows that much more ... hemophilia patients in the developing world, and that the current ...
... SINGAPORE, Nov. 16 /PRNewswire-Asia/ -- Retail sales ... in the first half of 2009 with,total consumption peaking in ... Contact Lens manufacturers. Positive sales,data showing a growth of 14% ... economic recovery that is being led by consumers spending. , ...
... of ketamine users has been published online today in ... Special K) use increasing faster than any other drug ... showing the consequences of repeated ketamine use provides valuable ... the study, researchers from University College London followed 150 ...
Cached Medicine News:Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 2Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 3Health News:2009 National Ergonomics Conference Opens in Las Vegas November 17 With Hundreds of Industry Leaders in Attendance 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 3Health News:Research highlights need to address hemophilia in developing world 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:First ever large-scale study of ketamine users published 2
Designed to securely hold scleral plugs during insertion and removal. The cross action handle is designed to reduce hand fatigue while grasping plug....
Ergotec Vetriretinal Instrument System. Ultra-fine 3.35 mm jaws. Angled 55 degrees. 20 gauge shaft. 30 mm in length. Blackened tip. Overall length from rear rotation knob to tip....
Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Left. Most popular size or model....
Shafts angled 45 degrees, 10 mm from tip to bend. 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....
Medicine Products: